-
Genesis MedTech Secures Chinese Market Approval for ArtiSential Laparoscopic Surgical Device
•
Singapore-based Genesis MedTech has announced that it has received market approval in China for its ArtiSential articulating laparoscopic surgical device. The device, originally developed by South Korean firm LivsMed, was exclusively licensed to Genesis for distribution and market development in China in a deal that took place in 2021. Innovative…
-
Shanghai Fosun Pharmaceutical Submits Daxibotulinumtoxin A (RT002) for NMPA Approval
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a market approval filing to the National Medical Products Administration (NMPA) in China for its in-licensed daxibotulinumtoxin A for injection (RT002). The drug has been filed for use in adult cervical dystonia, marking a significant step…
-
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-1703 Clinical Study
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its anti-interleukin-5 (IL-5) antibody, SHR-1703. The drug candidate is set to be assessed as a treatment for eosinophilic granulomatous polyangiitis, a rare…
-
C-Mer Eye Care Holdings Ltd Partners with Hong Kong Ophthalmologist for Novel Drug Development
•
China-based C-Mer Eye Care Holdings Ltd (HKG: 3309) has announced the establishment of a joint venture with Doctor Dennis Lam, a distinguished ophthalmologist in Hong Kong. The joint venture, valued at a market capitalization of HKD 50 million (USD 6.4 million), is aimed at focusing on the development of innovative…
-
ChengDu ShengNuo Biotechnology Aims to Raise RMB 160 Million for Peptide Drug CDMO Expansion
•
China-based ChengDu Shengnuo Biotechnology Co., Ltd., (SHA: 688117) has announced plans to raise up to RMB 160 million (USD 22 million) through a private placement. The net proceeds from this capital increase are designated for Contract Development and Manufacturing Organization (CDMO) work on innovative peptide drugs, the industrialization of active…
-
Peijia Medical Receives NMPA Approval for DCwire Micro Guide Wire Device in China
•
Peijia Medical Ltd (HKG: 9996), a leading Chinese firm in the neurointerventional field, has announced receiving market approval from the National Medical Products Administration (NMPA) in China for its DCwire micro guide wire device. This milestone marks the company’s 15th neurointerventional product approval in China, highlighting its commitment to advancing…
-
Chime Biologics, Leads Biolabs, and BeiGene Form Strategic Partnership for LAG-3 mAb LBL-007
•
Wuhan-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics has signed a strategic cooperation agreement with Nanjing-based Leads Biolabs and Beijing firm BeiGene Inc., (NASDAQ: BGNE, HKG: 6160). The cooperation focuses on the development and global manufacturing of LBL-007, a LAG-3 monoclonal antibody (mAb). BeiGene’s Acquisition and Global Rights to…
-
Sirnaomics Ltd Partners with Edirna Inc. to Advance RNA Editing Therapy
•
Sirnaomics Ltd (HKG: 2257), a leading company in the field of RNA therapeutics, has announced a strategic partnership with US-based Edirna Inc., a newly launched biotech startup focused on RNA editing therapy. Funding and Licensing Agreement DetailsUnder the terms of the agreement, Sirnaomics is providing start-up funding to support Edirna’s…
